申请人:Japan Tobacco, Inc.
公开号:EP1884513A1
公开(公告)日:2008-02-06
The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I):
wherein Ring Q represents an aryl or heteroaromatic group, R1 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, R2 represents a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or an azido group, R3 represents a halogen atom, a hydroxyl group, a C1-6 alkyl group, a halo C1-6 alkyl group, a C1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C1-6 alkylsulfonylamino group, R4 and R5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C1-6 alkyl group, a C3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.
本发明提供了一种具有肝糖原磷酸化酶抑制活性并可用作糖尿病治疗或预防剂的吡唑化合物,该吡唑化合物由以下通式(I)表示:
其中环 Q 代表芳基或杂芳基,R1 代表氢原子、卤素原子、C1-6 烷基或 C1-6 烷氧基,R2 代表卤素原子、C1-6 烷基、C1-6 烷氧基或叠氮基,R3 代表卤素原子、羟基、C1-6 烷基、卤代 C1-6 烷基、C1-6 烷氧基、叠氮基、氨基、酰氨基或酰胺基、R4 和 R5 彼此相同或不同,代表氢原子、取代或未取代的 C1-6 烷基、C3-8 环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14 芳基、杂芳基或类似基团,或其药理学上可接受的盐。